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phenylphosphonium; DMMQ, 30-demethoxyMitoQ; MDA, malondialdehyde; MDR,
multidrug resistance; MitoQ, 10-(60-ubiquinonyl)decyltriphenylphosphonium;
ROS, reactive oxygen species; SkQ1, 10-(60-plastoquinonyl)decyltriphenylphospho-
nium; SkQ3, (60-methylplastoquinonyl) decyltriphenylphosphonium; SkQR1,
10-(60-plastoquinonyl) decylrhodamine 19; SkQT1(p), 10-(60-toluquinonyl) decyl-
triphenylphosphonium; SkQT1(m), 10-(50-toluquinonyl) decyltriphenylphosphoni-
um; SkQT1, a mixture of SkQT1(p) and SkQT1(m) in proportion of 1.4:1; SkQTR1,
10-(60-toluquinonyl) decylrhodamine 19; TQ, thymoquinone
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CancerSince the times of the Bible, an extract of black cumin seeds was used as a medicine to treat many
human pathologies. Thymoquinone (2-demethylplastoquinone derivative) was identiﬁed as an
active antioxidant component of this extract. Recently, it was shown that conjugates of plastoqui-
none and penetrating cations are potent mitochondria-targeted antioxidants effective in treating
a large number of age-related pathologies. This review summarizes new data on the antioxidant
and some other properties of membrane-penetrating cationic compounds where 2-demethylplasto-
quinone substitutes for plastoquinone. It was found that such a substitution signiﬁcantly increases a
window between anti- and prooxidant concentrations of the conjugates. Like the original plastoqui-
none derivatives, the novel compounds are easily reduced by the respiratory chain, penetrate
through model and natural membranes, speciﬁcally accumulate in mitochondria in an electropho-
retic fashion, and strongly inhibit H2O2-induced apoptosis at pico- and nanomolar concentrations in
cell cultures. At present, cationic demethylplastoquinone derivatives appear to be the most promis-
ing mitochondria-targeted drugs of the quinone series.
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Quinones as mitochondria-targeted antioxidants
Mitochondria are the only intracellular organelles whose inte-
rior is negatively charged relatively to the exterior [1,2]. This fact
can be used to speciﬁcally address various compounds to mito-
chondria. To this end, it was suggested to combine the transported
compound with a positively charged ion easily penetrating
through biomembranes [3,4]. To make an ion permeable for mem-
branes, its ionized atom should be surrounded by bulky hydropho-
bic residues that delocalize the electric charge of this atom [1,2,5].
Such a principle was employed to construct mitochondria-targeted
antioxidants [5–18]. Among them, some quinone derivatives
proved to be the most active (Fig. 1). As was found in our group,
the antioxidant activity measured in isolated mitochondria treated
with Fe2+ and ascorbate increases in the series: 10-(60-ubiquino-
nyl)decyltriphenylphosphonium (MitoQ) < 30-demethoxyMitoQ
(DMMQ) = (60-methylplastoquinonyl) decyltriphenylphosphonium
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(SkQ1) [15,16]. Thus, substitutions of methoxy group by methyl
and methyl group by an H atom seem to be favorable for antioxi-
dant activity. It would be interesting to continue this quinone ser-
ies by substituting one more methyl group in plastoquinone by an
H atom, just as it occurs in 2-demethylplastoquinone, an interme-
diate of plastoquinone biosynthesis [19] and in so-called thymoqui-
none (Fig. 1A), a plant antioxidant responsible for many favorable
pharmacological effects of black cumin (see below, Section 3).
We studied thymoquinone-like derivatives conjugated with pene-
trating cations, namely decyltriphenylphosphonium (in SkQT1)
and decylrhodamine 19 (in 10-(60-toluquinonyl) decylrhodamine
19 (SkQTR1)) (Fig. 1B). In the next section, some results of this
study are reviewed.Fig. 1. Formulas of certain compounds considered in this review. (A) Mitochondria-targe
(B) Cationic quinol derivatives of SkQ series and their analogs lacking quinol residue.2. Cationic thymoquinone derivatives: effect on model
membranes, isolated mitochondria and cell cultures
SkQT1 and SkQTR1 were synthesized in essentially the same
way as their plastoquinone analogs, SkQ1 and 10-(60-plastoquino-
nyl) decylrhodamine 19 (SkQR1) [15]. SkQT1 samples were a mix-
ture of p andm isomers (Fig. 1B) in the proportion of 1.4:1. SkQTR1
was puriﬁed as p isomer, like other SkQs [15].
In the ﬁrst series of experiments, generation of diffusion poten-
tial of SkQT1 on bilayer planar phospholipid membranes (BLM)
was demonstrated. Like other penetrating cations [2,4], the
concentration gradient of SkQT1 was found to generate an
electric potential difference, the compartment with lower
[SkQT1] being positively charged due to downhill transmembraneted cationic quinone derivatives and thymoquinone. R, decyltriphenylphosphonium.
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potential difference (Dw) reached the theoretical value (about
60 mV per 10-fold concentration gradient of the penetrating cat-
ion, Fig. 2A).
When SkQTR1 was used instead of SkQT1, the BLM responses
were more complicated. In this case, the theoretical value of the
diffusion potential could be observed only at acidic pH, the maxi-
mal Dw being obtained at pH 4.0 (see Supplemental information,
Fig. S1A and B). The effect was biphasic since Dw decayed with
time. If a pH gradient was increased across BLM, an H+ diffusion
potential was generated (Fig. 2B). Such an effect was observed even
without adding fatty acids which were required when SkQ1 substi-
tuted for SkQTR1 [20]. These relationships can be explained by the
fact that rhodamine 19 (the cationic group of SkQTR1) per se can
operate as a protonophore, being a weak base (protonophorous
properties of SkQR1 were already described elsewhere [21]). Pro-
tonophorous effect of SkQTR1 disappeared at acidic pH when the
concentration of deprotonated SkQTR1 became rate-limiting. This
effect increased in time after creation of the transmembrane
SkQTR1 gradient, most probably due to slow saturation by SkQTR1
of the half-membrane leaﬂet facing the compartment of low
[SkQTR1].
In the next experiments, SkQT1 and related compounds were
studied in isolated mitochondria in vitro. SkQT1, like SkQ1
[15,16], was found to be a rechargeable antioxidant. Fig. 3A
shows that the oxidized form of SkQT1 is reduced by the respira-
tory chain in an antimycin- and myxothiazol-sensitive manner.
Similar properties are inherent in thymoquinone (Fig. 3B) and
SkQ1 [15,16,22].
As is shown in Fig. 3C, SkQT1 prevents formation of malondial-
dehyde (MDA) in mitochondria treated with Fe2+ and ascorbate,
being almost 10- and 100-fold more active than SkQ1 and thymo-
quinone, respectively.
Fig. 3D demonstrates the inhibiting effect of SkQT1 and SkQ1 on
H2O2 production by isolated rat heart mitochondria during the re-
verse electron transfer from succinate to NAD+. It is seen that SkQ1
lowers this production, in line with our previous observations [17],
depicting a pronounced optimum since an inhibition observed at
low SkQ1 concentrations changes to activation when the concen-
tration increases. Experiments on SkQT1 also revealed such a bi-
phasic action, the window between inhibiting and activating
concentrations being much larger than that for SkQ1 (600 folds
for SkQT1 vs 20 folds for SkQ1).Fig. 2. Responses of SkQT1 and SkQTR1 in BLM. To form BLM, synthetic diphythanoylphos
10-fold SkQT1 gradient. The response was initiated by adding 2 lM SkQT1 to one of comp
0.2 lM. Incubation mixture, 1 mM KCl, 1 mM Tris-Mes, pH 6.5. (B) Protonophorous acti
Addition of KOH to one of the compartments shifted pH to 9.5. For details of the methoHigh (micromolar) levels of both SkQ1 and SkQT1 decrease
membrane potential in animal (Fig. 3E) and yeast (not shown)
mitochondria. Moreover, both compounds strongly potentiated a
Dw decrease caused by palmitate (Fig. 3F), an effect accounted
for by facilitating palmitate anion translocation by these penetrat-
ing cations [20].
It was also found that SkQT1 stimulated State 4 respiration
(Fig. S2A), which can be explained by discharge ofDwwith electro-
phoretic movement of SkQT1 and cycling of endogenous fatty acids
[15,20]. At high concentrations, SkQ1 and SkQT1 inhibited State 4
and State 3 respiration of mitochondria utilizing both NAD+ sub-
strates and a-glycerophosphate (Fig. S2A–C).
In Fig. 4, effects of SkQT1 and SkQTR1 on cultures of human cells
were tested. As shown in Fig. 4A, SkQTR1 speciﬁcally stains mito-
chondria in intact human ﬁbroblasts, resembling in this respect
previously studied SkQR1 [15–17]. In Fig. 4B, antiapoptotic effects
of SkQT1, SkQTR1, SkQ1, SkQR1, C12TPP and dodecyl rhodamine 19
(C12R1) were compared. It is seen that the SkQTs are more efﬁcient
than the SkQs in preventing H2O2-induced apoptosis. They inhib-
ited apoptosis at lower concentrations and suppressed this process
more strongly than SkQs. Like other SkQs, SkQTs prevented frag-
mentation of elongated mitochondria (‘‘thread? grain transi-
tion’’), accompanying apoptosis (not shown).
In the next series of experiments, we examined a novel effect of
our antioxidants, i.e., inhibition of growth of human sarcoma cells.
One can see in Fig. 4C that low concentrations of SkQ1, SkQR1 and
SkQT1 are inhibitory for a culture of human rhabdomyosarcoma.
Effective concentrations were 0.02 nM, 0.2 nM and 2 nM for
SkQ1, SkQR1 and SkQT1, respectively. Further study revealed that
non-targeted antioxidants can substitute for SkQ but at about 1
million-fold higher concentrations (Trolox, 0.1 mM; N-acetyl cys-
teine, 1 mM). The uncoupler FCCP (1 lM) completely abolished
the SkQ inhibition. Dodecyltriphenylphosphonium (C12TPP) and
C12R1, penetrating cations lacking antioxidant (quinone) residue,
were inactive up to micromolar concentrations. Fibrosarcoma
and osteosarcoma cells were also antioxidant-sensitive to some
degree, while human ﬁbroblasts, cardiomyocites H9C2 and myo-
blasts C2C12 appeared to be resistant. The mechanism of growth
inhibition consisted in (i) activation of apoptosis sensitive to
zVADfmk and (ii) arrest of the cell cycle at G2/M stage (not shown
in ﬁgures).
It should be stressed that the series of antioxidant active con-
centrations SkQs Trolox > N-acetyl cysteine is in line with ourphatidyl chlorine dissolved in decane was used. (A) Diffusion potential generated by
artments separated by BLM. Initial SkQT1 concentrations in both compartments was
vity of SkQTR1. Incubation mixture, 300 nM SkQTR1, 1 mM KCl, 1 mM Tris, pH 8.5.
ds, see [15,64].
Fig. 3. Effects of quinone derivatives on isolated mitochondria. (A) Reduction of SkQT1 by rat heart mitochondria. Mitochondria were isolated after Palmer et al. [65].
Incubation mixture, 2.5 mM succinate, 2 lM rotenone, 250 mM sucrose, 1 mM EDTA, 10 mMMops-KOH, pH 7.4, mitochondria, 0.25 mg/ml. Reaction was initiated by adding
10 lM SkQT1 at zero time. Where indicated, 1 lM antimycin A or 1 lMmyxothiazol were added. Aminco DW200 was employed to measure light absorbance at 270 nm. (B)
Reduction of thymoquinone by mitochondria. Conditions as in (A) but thymoquinone was added instead of SkQT1. (C) Inhibition of malondialdehyde formation by rat heart
mitochondria in the presence of Fe2+ and ascorbate. Amount of malondialdehyde was measured by means of its reaction with thiobarbituric acid (for procedure, see [15]). The
light absorbance was read at 532 nm. (D) Effects of SkQ1 and SkQT1 on H2O2 production by rat heart mitochondria in State 4. Rat heart mitochondria (100 lg) were pre-
incubated 1 min. at constant stirring at 25 C in 2 ml solution containing 250 mM sucrose, 10 mM MOPS, pH 7.4, 1 mM EDTA, 5 lM Amplex Red. Then 5 units of horseradish
peroxidase were added. Hydrogen peroxide production was initiated by subsequent addition of 10 mM succinate. Data presented as mean ± S.E. (E) Effect of SkQ1 and a
mixture of SkQT1(p) and SkQT1(m) in proportion of 1.4:1 (SkQT1) on the membrane potential in rat heart mitochondria. Incubation mixture, 250 mM sucrose, 1 mM EDTA, 10
mM MOPS, 15 lM safranine O, 5 mM succinate and 2 lM rotenone. For other conditions and methods, see [15]. (F) SkQ1 and SkQT1 potentiate DW decrease caused by
palmitate in yeast mitochondria. Incubation mixture, 0.6 M mannitol, 0.5 mM EDTA, 0.2 mM Tris–phosphate (pH 7.2), 20 mM succinate, 20 lM safranine O, and Yarrowia
lipolytica mitochondria (0.5 mg protein 1 ml). For methods, see [5].
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However, this range inside the SkQ group, i.e.,
SkQ1 > SkQR1 > SkQTR1, is unusual (Fig. 4C). One of possible expla-
nations might consist in different rate of pumping of these com-
pounds from the cell by multidrug resistance (MDR) ATPase [24].
In fact, it was found (Fig. 4D and Fig. S3A and B) that SkQTR1 accu-
mulation much smaller in the chemotherapy-resistant human
myeloid leukemia K562 cells. The accumulation was stimulated
by pluronic L61, an inhibitor of the MDR pump [25–27]. Compari-
son of accumulation of SkQR1 and SkQTR1 by cancer cells (K562,
Fig. 4D, and Fig. S3A and B; Hela, Fig. 4E) and immortalized 3T3
ﬁbroblasts (Fig. 4F) and by normal cells (human ﬁbroblasts,
Fig. 4G) clearly showed that the rate of this process is much slower
for SkQTR1 than for SkQR1 provided cancer cells with induced
MDR pumps were studied. The difference between SkQTR1 and
SkQR1 strongly decreased in cancer cells without MDR pumps.
Normal cells, such as ﬁbroblasts, accumulate both compounds with
one and the same rate. As found by Gate et al. [28], methylation of
anthracyclines inhibits the rate of their accumulation in cancer
cells due to the suppression of the activity of the MDR pump. This
may explain the above-described relationships if we take into ac-
count that SkQR1 can, in fact, be regarded as methylated derivative
of SkQTR1 (see above, Fig. 1B).
3. Comparison of effects of thymoquinone, SkQs and SkQTs
As shown in the preceding section, thymoquinone-like analogs
of SkQ1 (i) are mitochondria-targeted antioxidants and (ii) theirantioxidant activity in isolated mitochondria and living cells are,
as a rule, higher than SkQ1. Historically, there is a principal differ-
ence between derivatives of plastoquinone and thymoquinone. The
formers were introduced as compounds of potential therapeutic
activity several years ago whereas thymoquinone-containing black
cumin oil has been known as a medicine for thousand years, being
mentioned in the Bible; it was described as the Melanthion of Hip-
pocrates and Dioscorides and as the Gith of Pliny. Later, the Pro-
phet Muhammad advised: ‘‘Hold onto use the black cumin, for it
has a remedy for every illness except death’’ [29,30].
Thymoquinone is a pre-dominant (25–60%) component of the
essential oil Nigella sativa, a 20–30 cm tall herb belonging to Ran-
unculaceae family [29,31,32]. It shows a very pleotropic favorable
effect on various human diseases, being curative for osteosarcoma
[33,34] and some other types of cancer [35–47], neuropathies
[48,49], nephropathies [50,51], arthritis [51–53], inﬂammation
[52–57], astma [58,59], sepsis [53], and decline in immune re-
sponses [29,35]. Remarkably, SkQs proved to be efﬁcient in the
majority of these diseases [14,16–18,23,60,61]. The difference in
therapeutic effects thymoquinone and SkQs is quantitative. SkQs
operate at much lower concentrations and their action is usually
more pronounced than those of thymoquinone. All these relation-
ships are hardly surprising. (i) Both SkQs [15,16] and thymoqui-
none [29,35,62,63] are antioxidants. (ii) To some degree,
thymoquinone, like SkQs, is speciﬁcally targeted to mitochondria
since both thymoquinone and SkQs are effectively recharged by
reduction in center i of mitochondrial complex III [16,22]. This
means that in non-mitochondrial membranes oxidized (inactive)
Fig. 4. Effects of SkQT1 and SkQTR1 on cell cultures. (A) SkQTR1 speciﬁcally stains mitochondria in human ﬁbroblasts. Fibroblasts were incubated with 100 nM SkQTR1 for
45 min or 200 nM MitoTracker Green (mitochondria-speciﬁc ﬂuorescent dye) for 15 min, and analyzed with an Axiovert microscope (Carl Zeiss) equipped with a Neoﬂuar
100 NA 1.3 objective. (B) Effect of penetrating cations on H2O2-induced apoptosis. Human ﬁbroblasts were pre-incubated for 24 h with various concentrations of SkQs and
their analogs lacking quinone (C12TPP or C12R1). Then 0.5 mM H2O2 was added. The number of living cells was estimated 24 h after H2O2 addition. For methods, see [15]. (C)
SkQs inhibit growth of the human rhabdomyosarcoma cells. Cells growth for one day or four days was measured in the absence (control) or in the presence of indicated
concentration of SkQR1, SkQ1 or SkQT1. (D) K562 myeloid leukemia cells with or without induction of MDR pumps were studied. The cells were loaded with 50 nM SkQR1 or
SkQTR1 for 90 min., washed and incubated for 30 min. Where indicated, pluronic L61 (plu) was added (60 lg/ml) on 10th min. before adding SkQ. Fluorescence was measured
by FACS (Beckman-Coulter FC 500). (E) HeLa cells were studied. 100 nM SkQs and 10 lM FCCP were used. (F) 3T3 cells were studied. (G) Human ﬁbroblasts were studied. In
(E), (F) and (G), the samples were washed on 45th or 60th min. with a medium containing no SkQs.
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(active) state. Therefore, in these membranes, quinol forms of
SkQ or thymoquinone can act as antioxidant only once. (iii) Higher
efﬁciency of SkQs comparing to thymoquinone (see, e.g., Fig. 3C) is
explained by their electrophoretic accumulation of such cations as
SkQs inside mitochondria [16,17] while thymoquinone cannot be
accumulated being electroneutral. Moreover, SkQs are amphiphilic
and, hence, have very high distribution coefﬁcient between a
membrane and a water phase [17]. This coefﬁcient appears to be
much lower for the thymoquinone. Besides, the SkQs being pene-
trating cations were shown to catalyze fatty acid cycling, decreas-
ing thereby Dw on mitochondrial membrane and inhibiting in this
way reactive oxygen species (ROS) production by respiratory chain
[20]. Thymoquinone lacking any cationic residues is incapable of
performing such a function. Thus, thymoquinone is less efﬁcient
antioxidant comparing with SkQT1 and SkQRT1 although it is, like
SkQs, mitochondria-targeted antioxidant being rechargeable by
the mitochondrial respiratory chain (Fig. 3B). It is not surprising,
therefore, that the list of diseases cured by thymoquinone resem-
bles that of the SkQ-cured diseases. It seems promising to con-
struct a new generation of mitochondrial medicines on the basis
of SkQT1 which is more efﬁcient than other SkQs. It is especially
interesting that SkQTR1 is a much better substrate for MDR pumps
of cancer cells. This pump expels SkQTR1 from cancer much faster
than SkQR1. In a normal cell, the amount of MDR pumps is negli-
gible and therefore SkQTR1 concentration in such cells should be
much higher than in tumors, an effect allowing to speciﬁcally pre-
serve tissues other than tumors at anticancer therapies [24]. Inves-
tigations into such a possibility are now in progress in our group.
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